ASP Isotopes Reports Key Developments in Helium, Silicon 28, and Radiopharmacy
Apr 17, 2026
ASP Isotopes CEO Paul Mann highlighted progress in helium production and Silicon 28 commercialization alongside a planned nuclear spin-off. The firm targets cash flow break-even in the second half of the year and $300 million EBITDA by 2031.
Show all 124 updates